|Day Low/High||81.42 / 82.72|
|52 Wk Low/High||73.69 / 89.09|
More than half of wealthy investors expect to live to 100. Here's what you need to know to make sure you don't outlive your savings.
Stocks finished sharply lower Tuesday, as corporate earnings disappoint investors.
Lilly's chairman and CEO David Ricks said in an earnings call that he was confident in the risk-benefit profile for both proposed doses of the new drug.
Overall, it was a very strong beat by the company, and we view the ever-important guidance raise as favorable.
U.S. stock futures rise while the yield on the 10-year Treasury flirts with 3%; Alphabet beats first-quarter earnings and revenue expectations but there are concerns about rising costs at the search giant; 3M, Coca-Cola and Caterpillar report earnings.
Forward looking valuations, except for Nvidia, are very low.
Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.
I think M&A activity will pick up markedly going forward across the industry.
Christopher Jensen to join Indiana-based Animal Health Company's Leadership Team
Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.
Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.
Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.
Today, Jim discusses Raytheon, tensions in Syria, bank earnings, Kohl's, Nordstrom and more!
The markets bounced back on easing trade tensions and the banks kicked off first-quarter earnings season.
The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.
Kohl's is a company with 100% of revenue coming from the United States.
Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.
For Women's History Month, Alpha Rising sat down with Nancy Lieberman, Of Counsel at Skadden, Arps. She was and still is the youngest person to ever make partner at her firm. She has worked on some of the biggest M&A deals in history -- and we should mention -- she's in a wheelchair and barely as use of her hands. Feel like a slacker yet? Good. Watch.
Traders should stay alert and nimble with LLY stock.
Former Executive Chairman Paul Jacobs is considering a leveraged buyout, which would be incredibly expensive and face tough regulatory scrutiny.
Jim Cramer focuses on Merck, Eli Lilly, Abbott Labs, Phillips 66, Five Below, and Cintas in the Lightning Round.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.